Oncologist and organizational factors associated with variation in breast cancer multigene testing

[1]  J. Radford.  Comparison of hospital mortality and readmission rates for Medicare patients treated by male vs female physicians , 2017, BDJ.

[2]  A. Amini,et al.  21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Maya B. Mathur,et al.  Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems. , 2016, Journal of oncology practice.

[4]  T. Lieu,et al.  Breast cancer multigene testing trends and impact on chemotherapy use. , 2016, The American journal of managed care.

[5]  K. Armstrong,et al.  Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Lyman,et al.  Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. , 2015, JAMA oncology.

[7]  S. Dusetzina,et al.  Use and Costs for Tumor Gene Expression Profiling Panels in the Management of Breast Cancer From 2006 to 2012: Implications for Genomic Test Adoption Among Private Payers. , 2015, Journal of oncology practice.

[8]  L. Enewold,et al.  Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy , 2015, Breast Cancer Research and Treatment.

[9]  D. Patt,et al.  Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer. , 2013, Journal of oncology practice.

[10]  J. Herman,et al.  Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Jane M. Young,et al.  Audit and feedback: effects on professional practice and healthcare outcomes. , 2012, The Cochrane database of systematic reviews.

[12]  Elena Parmelli,et al.  Local opinion leaders: effects on professional practice and health care outcomes. , 2011, The Cochrane database of systematic reviews.

[13]  Ingvar Andersson,et al.  Invasive breast cancer. , 2011 .

[14]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Ben C. Juricek.  Generalized Linear Mixed-Effects Models in R , 2003 .

[16]  J. Robbins,et al.  The Influence of Gender on Physician Practice Style , 1995, Medical care.

[17]  V. Strecher,et al.  Are patients of women physicians screened more aggressively? , 1995, Journal of General Internal Medicine.

[18]  Gimpelson Rj.  Preventive care for women--does the sex of the physician matter? , 1994 .

[19]  C. Clancy,et al.  Physician Gender Bias in Clinical Decisionmaking: Screening for Cancer in Primary Care , 1993, Medical care.

[20]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[21]  Teresa Y. Lin,et al.  The Kaiser Permanente Northern California Adult Member Health Survey. , 2016, The Permanente journal.

[22]  Nilofer Merchant.  When TED Lost Control of Its Crowd , 2013 .

[23]  B. Ljung,et al.  Invasive breast cancer. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[24]  N. Lurie,et al.  Why Do Patients of Female Physicians Have Higher Rates of Breast and Cervical Cancer Screening , 1997 .

[25]  S Greenland,et al.  The impact of confounder selection criteria on effect estimation. , 1989, American journal of epidemiology.